Olympus Shares Plummet Over 5% Following CEO Resignation Amid Drug Allegations

Olympus Corporation’s shares fell over 5% on Monday after the resignation of CEO Stefan Kaufmann, who stepped down amid allegations of illegal drug purchases. The company has appointed former CEO Yasuo Takeuchi to lead temporarily as it navigates this corporate crisis.

Key Takeaways

• Olympus CEO Stefan Kaufmann resigned following allegations of illegal drug purchases.
• The company’s shares dropped by 6%, marking their largest decline in nearly three months.
• Yasuo Takeuchi, the former CEO, will temporarily retake the helm.

Background of the Allegations

The allegations against Kaufmann surfaced recently, prompting an immediate investigation by Olympus’s Board of Directors. The board, in consultation with external legal counsel, concluded that Kaufmann’s actions were inconsistent with the company’s global code of conduct and core values. The specific details regarding the source of the allegations have not been disclosed.

Kaufmann, who had been with Olympus for over 20 years, took on the CEO role in April 2023. His tenure was marked by efforts to expand the company’s medical equipment business and address regulatory issues that had previously plagued the organization.

Market Reaction

Following the announcement of Kaufmann’s resignation, Olympus shares experienced a significant drop of 6%, which is the largest single-day decline in nearly three months. This decline comes despite a 16% increase in the company’s stock since Kaufmann took over, which is notably lower than the 38% rise in the Nikkei 225 index during the same period.

Leadership Transition

In light of the recent developments, Yasuo Takeuchi, who previously led Olympus, will assume the CEO position temporarily. Takeuchi had been instrumental in steering the company through a series of asset sales and had focused on enhancing Olympus’s digital technology and robotics capabilities.

Historical Context

Olympus has a history of corporate scandals, including a significant accounting fraud case that was exposed by former CEO Michael Woodford in 2011. This incident involved overpaying for acquisitions to conceal losses, leading to Woodford’s dismissal shortly after his appointment. The company has faced scrutiny in the past, including a 2015 incident involving Toyota executive Julie Hamp, who was arrested in Japan for allegedly importing a controlled substance.

Future Outlook

As Olympus navigates this challenging period, the company will need to reassure investors and stakeholders about its commitment to ethical practices and corporate governance. The return of Takeuchi may provide some stability, but the long-term impact of Kaufmann’s resignation on Olympus’s strategic direction remains to be seen. Investors will be closely monitoring the company’s next steps as it seeks to recover from this setback and restore confidence in its leadership and operations.

Sources

• Olympus CEO ousted after allegation of illegal drug purchase, shares slump | Reuters, Reuters.